Gastro-entérologie5 articles

Impact 2

Gut microbiota-regulated glutathione metabolic rhythms restore obesity-induced colonic inflammatory oscillations.

Publié: 2026-12-31

Gut microbes

MediLens Indexé: 2026-05-11

The study investigates the impact of obesity on circadian inflammatory rhythms, a key aspect of metabolic syndrome. It demonstrates that a high-fat diet disrupts microbiota-regulated glutathione metabolism, leading to altered colonic inflammatory rhythms. The use of fructo-oligosaccharide (FOS) a...

Lire sur PubMed

Impact 2

Endoscopic grading of gastric intestinal metaplasia and microvascular pattern for assessing gastric cancer risk: a prospective study.

Publié: 2026-12-01

Annals of medicine

MediLens Indexé: 2026-05-12

This study validates the diagnostic accuracy of the endoscopic grading of gastric intestinal metaplasia (EGGIM) for identifying high-risk gastric intestinal metaplasia (GIM) patients. A total of 144 patients were evaluated, revealing an area under the curve (AUC) of 0.885 for EGGIM in diagnosing ...

Lire sur PubMed

Impact 3

Significant Intra-pancreatic Fat Deposition as an Independent Prognostic Factor in High-grade Pancreatic Neuroendocrine Neoplasms.

Publié: 2026-05-11

Annals of surgical oncology

MediLens Indexé: 2026-05-12

This study evaluates the prognostic value of significant intra-pancreatic fat deposition (IPFD) in patients with high-grade pancreatic neuroendocrine neoplasms (panNENs). Among 87 patients, 27.6% exhibited significant IPFD, which was linked to worse overall and disease-specific survival outcomes....

Lire sur PubMed

Impact 2

Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.

Publié: 2026-05-11

Inflammatory bowel diseases

MediLens Indexé: 2026-05-12

This systematic review evaluated the efficacy of advanced therapies for treating extraintestinal manifestations (EIMs) in inflammatory bowel diseases (IBDs). It included 49 studies, revealing that TNF antagonists and JAK inhibitors were effective for musculoskeletal EIMs, with response rates of 6...

Lire sur PubMed

Impact 2

Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report.

Publié: 2026-05-11

Acta oncologica (Stockholm, Sweden)

MediLens Indexé: 2026-05-12

This study investigates the effectiveness of pembrolizumab in treating advanced squamous cell carcinoma of the anal canal (SCCA) in a real-world cohort of 37 Danish patients. The objective response rate was 13.5%, with a clinical benefit rate of 48.6%. Median progression-free survival was 4.0 mon...

Lire sur PubMed

Tendances de la Recherche Médicale

Gastro-entérologie5 articles

Gut microbiota-regulated glutathione metabolic rhythms restore obesity-induced colonic inflammatory oscillations.

Endoscopic grading of gastric intestinal metaplasia and microvascular pattern for assessing gastric cancer risk: a prospective study.

Significant Intra-pancreatic Fat Deposition as an Independent Prognostic Factor in High-grade Pancreatic Neuroendocrine Neoplasms.

Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.

Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report.

Recevez des résumés quotidiens personnalisés